文献速递肝病

替诺福韦二吡呋酯单药治疗多药耐药慢性乙肝病毒感染的长期疗效

Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-10-26

多中心、前瞻性、真实世界队列研究纳入韩国8家三级医院的423例多药耐药慢性乙肝患者,分别接受替诺福韦二吡呋酯(TDF)单药(174例)或TDF联合治疗(249例),中位随访180周。两组在各时间点的累积病毒学应答率无显著差异,长期TDF单药抗病毒疗效不劣于联合治疗。

要点

  • 多药耐药慢性乙肝患者中,TDF单药与联合治疗的长期病毒学应答率无显著差异。
  • HBV DNA低于4.0 log10 IU/mL和未检出阿德福韦耐药突变与病毒学应答相关。
  • 年龄、性别、肝硬化、HBeAg状态和肾功能对病毒学应答无显著影响。

核心结论

  • 在多中心真实世界队列研究中,长期使用TDF单药治疗对多药耐药慢性乙肝患者的抗病毒疗效不劣于TDF联合治疗。

研究设计与样本

  • 多中心、前瞻性、真实世界队列研究,从韩国8家三级医院招募423例对核苷(酸)类似物耐药的慢性HBV感染患者。
  • 患者接受TDF单药挽救治疗(174例)或TDF联合治疗(249例),中位随访180周。
  • 病毒学应答定义为血清HBV DNA低于20 IU/mL。

主要发现

  • TDF单药组与联合治疗组在48周的累积病毒学应答率分别为71.7%和68.9%,96周分别为85.1%和84.2%,144周分别为92.1%和92.7%,192周分别为93.4%和95.7%,240周分别为97.7%和97.2%,两组间均无显著差异。
  • 在多药耐药患者中,血清HBV DNA低于4.0 log10 IU/mL(比值比2.478,95%CI 1.959-3.135,P<.001)和不存在阿德福韦耐药相关突变(比值比1.570,95%CI 1.279-1.926,P<.001)与病毒学应答相关。
  • 不同年龄、性别、有无肝硬化、HBeAg阳性与否及肾功能状态的患者间病毒学应答均无显著差异(所有P>.05)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There are no globally agreed upon treatment guidelines for patients with chronic hepatitis B virus (HBV) with multidrug resistance (MDR). We conducted a multicenter, prospective, real-world cohort study of effects of tenofovir disoproxyl fumarate (TDF) monotherapy and TDF-based combination therapy, as rescue therapy, in patients with multidrug-resistant chronic HBV infections. METHODS: We recruited patients with chronic HBV infection with resistance to antivirals from 8 tertiary hospitals in Korea. Patients (n=423) received rescue therapy with TDF monotherapy (n=174) or TDF-based combination therapy (n=249). The median follow-up period was 180 weeks. A virologic response was defined as a serum HBV DNA level of <20 IU/mL. RESULTS: Cumulative rates of virologic response did not differ significantly between the groups that received TDF monotherapy vs combination therapy at 48 weeks (71.7% vs 68.9%), 96 weeks (85.1% vs 84.2%), 144 weeks (92.1% vs 92.7%), 192 weeks (93.4% vs 95.7%), or 240 weeks (97.7% vs 97.2%). Serum levels of HBV DNA below 4.0 log10 IU/mL (odds ratio, 2.478; 95% CI 1.959-3.135; P < .001) and the absence of mutations associated with resistance to adefovir (odds ratio, 1.570; 95% CI 1.279-1.926; P < .001) were associated with virologic response in patients with MDR. There was no significant difference of virologic response among patients of different ages, sex, patients with vs without cirrhosis, positivity for hepatitis B e antigen, or renal function (all P > .05). CONCLUSION: In a multicenter, real-world cohort study, long-term use of TDF monotherapy showed non-inferior antiviral efficacy compared with that of TDF-based combination therapy in patients with MDR.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Lee HW, Park JY, Lee JW, et al. Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection. Clin Gastroenterol Hepatol. 2018. PMID: 30613003. doi:10.1016/j.cgh.2018.10.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。